Literature DB >> 7607216

Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials.

M L Cunningham1, A H Fairlamb.   

Abstract

Trypanothione reductase was purified to homogeneity from Leishmania donovani promastigotes transfected with the expression plasmid pTEX-LdTR. The physical, spectral and kinetic properties were found to be similar to those obtained from other pathogenic trypanosomatids. The substrates trypanothione disulfide and NADPH exhibit Michaelis-Menten saturation kinetics with Km values of 36 microM and 9 microM, respectively, the former yielding a kcat/Km of 5.0 x 10(6) M-1 s-1. Like other trypanothione reductases, the leishmania enzyme is unable to use glutathione disulfide as substrate. Both trypanothione reductase and the analogous mammalian enzyme, glutathione reductase, are inhibited by trivalent but not pentavalent anti-leishmanial antimonials. Inhibition by trivalent sodium antimonyl gluconate (Triostam) occurs in a time-dependent manner, with the pseudo-first-order rate constants of inhibition being linearly related to drug concentration. Inhibition proceeds until an apparent equilibrium between active enzyme/free drug and inactive enzyme-drug complex is reached. MelT, an adduct of melarsen oxide and dihydrotrypanothione which is a competitive inhibitor of the disulfide binding site of trypanothione reductase, confers protection against Triostam. Prior reduction of the catalytically active disulfide bridge by NADPH is essential for inhibition. Spectral analysis shows that the broad absorbance band centred on 530 nm, characteristic of the charge-transfer complex in the two-electron-reduced EH2 enzyme, is lost upon addition of Triostam. Further spectral changes resemble those associated with reduction of the FAD prosthetic group to FADH2. Inhibition by Triostam is readily reversed by dilution or addition of the dithiols 2,3-dimercaptopropanol, 2,3-dimercaptosuccinate or dithiothreitol, but not dihydrotrypanothione, suggesting that this trypanosomatid-unique metabolite is unlikely to protect the enzyme from inhibition in whole cells. A mechanism consistent with these observations is proposed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607216     DOI: 10.1111/j.1432-1033.1995.tb20583.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  36 in total

1.  Possible links between sickle cell crisis and pentavalent antimony.

Authors:  Daniel Garcerant; Luisa Rubiano; Victor Blanco; Javier Martinez; Nancy C Baker; Noah Craft
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

Review 2.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase.

Authors:  Chris J Hamilton; Ahilan Saravanamuthu; Ian M Eggleston; Alan H Fairlamb
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

4.  Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival.

Authors:  J Tovar; M L Cunningham; A C Smith; S L Croft; A H Fairlamb
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity.

Authors:  Derek C Martyn; Deuan C Jones; Alan H Fairlamb; Jon Clardy
Journal:  Bioorg Med Chem Lett       Date:  2006-12-09       Impact factor: 2.823

6.  Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues.

Authors:  Rajiv Kumar Verma; Vijay Kumar Prajapati; Girijesh Kumar Verma; Deblina Chakraborty; Shyam Sundar; Madhukar Rai; Vikash Kumar Dubey; Maya Shankar Singh
Journal:  ACS Med Chem Lett       Date:  2012-01-18       Impact factor: 4.345

7.  Linking in vitro and in vivo survival of clinical Leishmania donovani strains.

Authors:  Manu Vanaerschot; Ilse Maes; Meriem Ouakad; Vanessa Adaui; Louis Maes; Simonne De Doncker; Suman Rijal; François Chappuis; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

8.  Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design.

Authors:  Ahilan Saravanamuthu; Tim J Vickers; Charles S Bond; Mark R Peterson; William N Hunter; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-04-21       Impact factor: 5.157

9.  A comparative study of methylglyoxal metabolism in trypanosomatids.

Authors:  Neil Greig; Susan Wyllie; Stephen Patterson; Alan H Fairlamb
Journal:  FEBS J       Date:  2008-12-03       Impact factor: 5.542

10.  Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi.

Authors:  Deuan C Jones; Antonio Ariza; Wing-Huen A Chow; Sandra L Oza; Alan H Fairlamb
Journal:  Mol Biochem Parasitol       Date:  2009-09-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.